| Title : Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications - Baladi_2000_Clin.Ther_22_1549 |
| Author(s) : Baladi JF , Bailey PA , Black S , Bouchard RW , Farcnik KD , Gauthier S , Kertesz A , Mohr E , Robillard A |
| Ref : Clin Ther , 22 :1549 , 2000 |
| Abstract : |
| PubMedSearch : Baladi_2000_Clin.Ther_22_1549 |
| PubMedID: 11192146 |